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Abstract An in-depth understanding of the different
groups that make up the HIV-infected population should
inform prevention and care. Using latent class analysis
(LCA) we identified seven groups with similar socio-
demographic and behavioral characteristics at enrolment in
the Swiss HIV Cohort Study: older gay men, younger gay
men, older heterosexual men, injection drug users, single
migrants, migrant women in partnerships and heterosexual
men and women. Outcomes of combination antiretroviral
therapy (ART) were analyzed in 1,633 patients starting
ART. Compared to older gay men, the probability of a
virologic response to ART was reduced in single migrants,
in older heterosexual men and in IDUs. Loss to follow-up
was higher in single migrants and IDUs, and mortality was
increased in older heterosexual men and IDUs. Socio-
behavioral groups identified by LCA allow insights above
what can be gleaned from traditional transmission groups,
and may identify patients who could benefit from targeted
interventions.
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Introduction
Highly active antiretroviral therapy (ART) has substan-
tially reduced morbidity and mortality in HIV-infected
patients [1]. However, mortality continues to be increased
compared to the general population in many patient groups
[2, 3], treatment fails in a substantial minority of patients
and loss to follow-up is common [4]. Social and behavioral
factors are important predictors of health outcomes [5]. In
HIV infection socio-demographic and behavioral charac-
teristics of patients have repeatedly been shown to be
Olivia Keiser and Ben Spycher contributed equally to this study.
The members of The Swiss HIV Cohort Study are given in the
acknowledgement.
The work was presented at the Conference of Retroviruses and
Opportunistic Infections (CROI 2010) in San Francisco.
O. Keiser (&)  B. Spycher  M. Egger
Institute of Social and Preventive Medicine (ISPM), University
of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland
e-mail: okeiser@ipsm.unibe.ch
A. Rauch
University Clinic for Infectious Diseases, Bern University
Hospital and University of Bern, Bern, Switzerland
A. Calmy
Division of Infectious Diseases, University Hospital Geneva,
Geneva, Switzerland
M. Cavassini
Division of Infectious Diseases, University Hospital Lausanne,
Lausanne, Switzerland
T. R. Glass
Basel Institute for Clinical Epidemiology and Biostatistics,
University Hospital Basel, Basel, Switzerland
D. Nicca
Division of Infectious Diseases, Cantonal Hospital St.Gallen,
St.Gallen, Switzerland
B. Ledergerber
Division of Infectious Diseases and Hospital Epidemiology,
University Hospital, University of Zu¨rich, Zu¨rich, Switzerland
123
AIDS Behav (2012) 16:245–255
DOI 10.1007/s10461-011-9971-5
associated with late diagnosis of the infection, and with
progression of the disease. For example, a collaborative
analysis of European and North American cohort studies
showed that mortality was lowest in gay men, somewhat
higher in heterosexually infected individuals and much
higher in people infected through injection drug use (IDU)
[3]. In contrast, a Canadian study found that mortality was
similar in IDUs and non-IDUs [6].
Previous studies generally focused on the main HIV
transmission groups or identified single socio-demographic
and behavioral characteristics that are independently
associated with the outcomes of interest. However, the
transmission groups consist of heterogeneous groups of
patients, including, for example, younger immigrants and
older Swiss patients who were infected heterosexually,
current and former IDUs, and young and older gay men.
Age is associated with adherence to ART [7] and there may
be synergistic effects between immune deficiency and
chronic immune activation, which accelerates ageing
[8, 9]. It is therefore likely that analyses of outcomes of
ART based on broad transmission groups will hide dif-
ferences within groups, and that the different composition
of transmission groups might explain conflicting results
between such studies [3, 6].
Studies that examined socioeconomic position (SEP)
and treatment outcomes have also found conflicting results.
Low SEP, poverty and minority ethnic groups were asso-
ciated with poorer prognosis [10, 11] but some studies
found no relationship [12, 13] or associations in some
groups only, for example in women [14]. It has been
suggested that a possible reason for these conflicting results
may be that SEP is mediated by a variety of factors that
differ between settings and that single measures of SEP, for
example income, and proxy measures such as ethnicity or
injection drug use, are insufficient to reliably capture SEP
in different populations and settings [15].
An alternative approach to analyzing differences
between transmission groups or levels of SEP is to examine
how relevant variables cluster across patients. Latent class
analysis (LCA) can be used for this purpose [16]. Origi-
nally developed in the social sciences, LCA is increasingly
used in medical research, for example to identify disease
phenotypes [17, 18] or to evaluate diagnostic tests in the
absence of a gold standard [19]. In the present study we
used LCA to examine the following hypotheses in the
Swiss HIV Cohort Study (SHCS), a large prospective
cohort that is representative of persons infected with HIV
in Switzerland [20]: (1) meaningful, distinct socio-demo-
graphic and behavioral groups can be identified in the
SHCS through LCA; (2) these groups differ from the main
HIV transmission groups and include groups that are not
directly observable using a single variable approach;
(3) group membership is associated with relevant treatment
variables (such as late initiation of ART or adherence) and
with treatment outcomes.
Methods
The Swiss HIV Cohort Study (SHCS)
The SHCS was established in 1988 as a nationwide, pro-
spective cohort study of HIV-infected participants who are
followed at one of seven study centers based at University
or Cantonal hospitals, or at a private practice or regional
hospital associated with a study center [20, 21]. A stan-
dardized questionnaire is used for data collection which is
completed by the treating physician. Socio-demographic
and behavioral data are recorded at enrolment (i.e., year of
birth, gender, nationality, ethnicity, education, profession,
region of origin, income, HIV test result, sexual orienta-
tion, presumed mode of HIV transmission). At each semi-
annual visit further socio-economic and behavioral data are
collected, including source of income, ability to work,
current IDU, partnerships and condom use. Antiretroviral
treatment, clinical events and hospitalizations are docu-
mented in detail. Completed questionnaires are sent to the
SHCS data centre where the data are entered and quality
checks are performed.
Transmission groups include gay men, heterosexually
infected patients, IDU, patients infected via blood products
and patients with unknown route of infection. HIV-1 RNA
is determined using the Roche Amplicor HIV-1 Monitor or
the Cobas-Taqman assay. Clinical AIDS diagnoses (Cen-
ters for Disease Control and Prevention [CDC] stage C) are
recorded by the treating physicians on the basis of the 1993
CDC criteria [22]. Hepatitis B (HBV) co-infection is
defined by a positive HBV surface antigen (HBsAg) and
hepatitis C (HCV) infection by a positive anti-HCV anti-
body test. Laboratory results are transferred automatically
from laboratories to the SHCS data centre. Data quality is
regularly checked by the data centre and a system with
incentives rewarding high quality of data is in place.
At all sites institutional review boards approved the
collection of data. All study participants provided informed
consent.
Eligibility Criteria and Definitions
All participants newly enrolled in the Swiss HIV Cohort
Study between 1st of January 2000 and August 2008 were
included in the LCA to identify socio-behavioral groups.
Participants who were treatment-naı¨ve and started ART at
or after enrolment were included in the analysis of treat-
ment outcomes. The closing date of the database for the
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present analysis was August 2008. ART was defined as
combination antiretroviral therapy consisting of at least
three drugs from at least two drug classes. Participants who
reported IDU within the last 6 months prior to registration
were classified as ‘current IDU’. All other participants who
reported IDU prior to registration were classified as ‘former
IDU’.
Latent Class Analysis (LCA)
We used LCA [16] to identify groups of individuals with
similar socio-demographic and behavioral characteristics at
enrolment into the cohort. The method assumes that the
population is composed of subpopulations (latent classes),
which are not directly observed but inferred from the
observed characteristics of individuals. Within each class,
the variables are assumed to be independent, i.e., all
associations between variables are assumed to arise from
the presence of different latent classes and within each
class heterogeneity is reduced. All relevant socio-
demographic and behavioral variables were included in the
LCA. Two authors (OK and BS) selected the variables and
both the selection of variables and the definitions of cate-
gories were done a priori and not modified later on. We
included the following variables: sex, age (\25, 25–34,
35–44, 45–54, C55 years), region of origin (Switzerland
and North-West Europe, Southern Europe, Sub-Saharan
Africa, Latin America, Asia/Eastern Europe, Other), pro-
fession (self employed, apprentice/trainee, higher man-
agement, middle management, employee, houseman/wife,
student), main source of income (employment, family
support, unemployment benefit or other insurance), sexual
orientation (gay, bisexual, heterosexual), partner (stable
partner only, stable and occasional partners, occasional
partners only, no partner), and history of IDU (never, for-
mer, current).
The models were fitted using Mplus software (Muthen
& Muthen, Los Angeles, CA, USA). The appropriate
number of classes was selected using the Bayesian infor-
mation criterion (BIC) [23]. Probabilities of belonging to
the different latent classes of a fitted model can be com-
puted for each individual based on his/her socio-demo-
graphic and behavioral characteristics. Individuals were
allocated to the groups for which they had the highest
membership probability [23].
Outcomes
Four outcomes were considered: virologic response, loss to
follow-up, all cause mortality and adherence to ART.
Virologic response was defined as suppression of HIV-1
viral load to\50 copies/ml at 6 months after starting ART
among patients who were followed for at least 6 months.
The value closest to 6 months (within 5–12 months) after
start of ART was used. A patient was considered lost to
follow-up if the last visit was more than 14 months before
the closing date of the database and the patient was not
known to have died. Only participants who potentially had
14 months of follow-up were included in the analysis of
loss from follow-up. Adherence had been assessed since
May 2003 by asking two questions at every visit: (1) How
often did you miss a dose in the last four weeks (every day,
more than once a week, once a week, once every second
week, once a month, never), (2) Did you not take drugs for
[24 h in the last four weeks? (yes or no). Good adherence
was defined as having missed no dose during the four
weeks preceding the most recent study visit.
Statistical Analysis
We used univariable and multivariable Cox regression for
time-to-event analyses of mortality and loss to follow-up
and logistic regression for virologic response and adherence.
Time was measured from the start of treatment to the date the
endpoints occurred, or the date of the last follow-up visit.
Models were adjusted for values at the start of ART: age,
CD4 cell count (0–49, 50–99, 100–199, 200–349, C350
cells/ll), viral load (\50–9,999, 10,000–99,999, C100,000
copies/ml), clinical stage (CDC stage A and B, or C) and
type of ART regimen (PI-based, NNRTI-based, other).
Some analyses were additionally adjusted for sex.
Missing values of CD4 cell counts and viral load at the
start of ART were imputed on the basis of whether the
patient died, age, sex, year of starting ART and CDC stage
of disease. In these imputations, values of the missing data
were randomly sampled from their predicted distributions.
Analyses were run on each of 20 datasets, and the results
combined with Rubin’s rules [24].
Analyses were done using Stata software (version 10,
Stata Corporation, College Station, Texas). Results are
presented as odds ratios (OR) or hazard ratios (HR).
Results
A total of 4,483 participants were included in the LCA. The
majority of participants (3,063; 68.3%) were men, median
age was 37 years (IQR 31–43 years) and the median CD4
cell count at enrolment was 359 cells/ll (IQR 206–540).
Distribution across groups of presumed transmission was
as follows: heterosexual (1,991 participants; 44.4%), gay
men (1,680; 37.5%), IDU (598; 13.3%) and other or
unknown (214; 4.8%). A total of 1,633 participants
(36.4%) starting ART were included in mortality analyses,
with a median duration of follow-up of 2.8 years (IQR
1.1–5.0 years). The remaining participants died or were
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lost to follow-up before starting ART, started ART before
enrolment or were still under follow-up without having
started ART (Fig. 1). Missing baseline values of CD4 cell
count were imputed in 163 patients (10.0%), and missing
viral load values in 340 patients (20.1%). The 2,850
patients who were excluded from the analysis of treatment
outcomes were more likely to be female (32.9 vs. 29.6%),
more likely to have a history of IDU (17.9 vs. 13.0%,
P \ 0.001), less likely to have a homosexual orientation
(32.8 vs. 39.7%, P = 0.03) and more likely to live without
external financial support (62.3 vs. 52.9%, P \ 0.001).
A total of 1,516 participants were included in the analysis
of loss to follow-up: 117 participants (7.2%) were excluded
because they were enrolled within 14 months before the
closing date. Overall 1,485 patients were included in the
analysis of adherence to ART: 148 (9.1%) were excluded
because they did not have data on adherence. Finally, 1,180
patients were included in the analysis of virologic response:
453 participants (27.7%) were excluded because they did not
have at least 6 months of follow-up (Fig. 1).
Socio-Behavioral Groups Identified by Latent Class
Analysis
A latent class model with seven classes was chosen, based
on the lower BIC value in this model compared to models
with fewer or more classes. Fig. 2 shows the formation of
the groups and the decrease in BIC values as the number of
classes increased. The group of older gay and bisexual men
was identified early on (G1 in model 2) and present in all
subsequent models, with some attrition to other groups.
The third group (G3) in model 3 included single migrants
and migrant women in stable partnership whereas the
second group (G2) later split into IDUs, heterosexual men
and women, and older heterosexual men. For 2,791
(62.3%) participants, the probability of belonging to the
group they were assigned to was C0.90, while for 433
(9.7%) participants this probability was \0.60, indicating
more ambiguous membership. The median probability
ranged from 0.82 (IQR 0.63–0.92) in the group of hetero-
sexual men and women to 0.99 (0.95–1.00) in IDUs.
The distribution of the variables included in the latent
class analysis across the seven groups is shown in Table 1
and Box 1 gives a summary description of the groups. All
socio-behavioral groups were dominated by one transmis-
sion group. For example, participants presumably infected
through heterosexual contacts dominated four socio-behav-
ioral groups: heterosexual men and women (729/884;
82.5%), older heterosexual men (298/431; 69.1%), single
migrants (403/444; 90.8%) and migrant women in partner-
ship (356/411; 86.6%). The group of heterosexual men and
women included some individuals presumably infected
through IDU (66/884; 7.5%). All were former IDUs. Also,
the group described as older heterosexual men included a
minority (96/431; 22.3%) of gay men. The six women who
were classified into the two groups of ‘gay men’ were all
lesbian women.
Characteristics at the Start of ART
CD4 cell count, clinical stage and prevalence of HCV and
HBV infection at start of ART are shown in Table 2. The
median CD4 count ranged from 175 cells/ll in heterosex-
ual men and women to 225 cells/ll in migrant women
Fig. 1 Inclusion of participants
into different analyses
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(Kruskal–Wallis v2 24.5, P \ 0.001). Substantial differ-
ences were also observed for the percentage of participants
in clinical stage C, which ranged from 8 to 23.9% (v2 17.3;
P = 0.008). The prevalence of HCV infection was highest
in IDUs, but also higher in heterosexual men and women
and older heterosexual men (v2 809.7; P \ 0.0001) than in
other groups. The prevalence of HBV infection was highest
in single migrants, migrant women in stable partnerships
and younger gay men and lowest in heterosexual men and
women. Differences were less pronounced between trans-
mission groups, and failed to reach conventional levels of
statistical significance for CD4 cell count and HBV
serology.
Outcomes
A total of 889 participants (75.3% of 1,180) suppressed
viral load at 6 months, 73 participants (4.8% of 1,516)
were lost to follow-up and 73 participants (4.5% of 1,633)
died. Table 3 presents OR or HR for viral suppression,
adherence to antiretroviral therapy, loss to follow-up and
mortality comparing socio-behavioral groups and trans-
mission groups. In crude and adjusted models the proba-
bility of viral suppression six months after therapy start
was reduced in IDUs, single migrants and older hetero-
sexual men, compared to older gay and bisexual men.
Similarly, adherence was worse in IDUs and in single
migrants. The risk of loss to follow-up was increased in
single migrants and IDUs, compared to older gay and
bisexual men. Compared to a category combining older gay
and bisexual men and younger gay men, mortality was
higher in older heterosexual men and IDUs.
Differences were again less pronounced across trans-
mission groups: there were no clear differences in virologic
response and participants infected through heterosexual
contacts were comparable to gay men with respect to loss
to follow-up. Mortality was higher in heterosexually
infected participants compared to gay men. As expected,
IDUs had a lower probability of virologic response, a
higher risk of loss to follow-up and higher mortality,
compared to gay men.
Discussion
We identified several socio-behavioral groups among HIV-
infected patients enrolled in the Swiss HIV cohort study
through LCA, in support of our first hypothesis. These
groups differed from the main HIV transmission groups
and include groups that are not directly observable using a
single variable approach, thus confirming our second
hypothesis. For example, we identified two distinct groups
Model 1 BIC=71687G1100%
Model 2 BIC=66670G148.0%
G2
52.0%
Model 3 BIC=65257G143.1%
G2
33.4%
G3
23.5%
Model 4 BIC=64699G138.0%
G2
24.8%
G3
14.0%
G4
23.2%
Model 5 BIC=64404G137.5%
G2
25.1%
G3
13.9%
G4
10.8%
G5
12.7%
Model 6 BIC=64214G135.1%
G2
4.1%
G3
24.9%
G4
13.9%
G5
 9.9%
G6
12.1%
Model 7 BIC=64076G135.0%
G2
3.5%
G3
19.7%
G4
 9.6%
G5
13.1%
G6
 9.9%
G7
 9.2%
Older gay Young Heterosexual Older IDU Single Migrant
and bisexual gay men and heterosexual migrants women in
pihsrentrapnemnemownemnem
Fig. 2 Stepwise identification
of socio-behavioral groups in
latent class analysis. The size of
shaded boxes is proportional to
the percentage of the 4,483
participants allocated to the
group. A model with seven
groups had the lowest BIC
(Bayesian Information
Criterion): in a model with eight
groups BIC increased to 64,112.
The seven groups of the final
model were assigned labels
according to their most pertinent
characteristics (see Box 1).
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of men infected through sex with men: younger gay men
were mainly from Latin America, Asia and Eastern Europe
and started ART with a lower median CD4 cell count
compared to older gay and bisexual men, who were pre-
dominantly Swiss. Most participants who had been infected
through heterosexual contacts belonged to one of four
Table 1 Distribution of the variables included in the latent class analysis across the seven socio-behavioral groups
Older gay and
bisexual men
Younger gay
and bisexual
men
Heterosexual
men and
women
Older
heterosexual
men
Injection
drug users
Single
migrants
Migrant women
in partnership
No. of participants 1568 (35.0) 156 (3.5) 884 (19.7) 431 (9.6) 589 (13.1) 444 (9.9) 411 (9.2)
No. of women 1 (0.1) 5 (3.2) 420 (47.5) 90 (20.9) 202 (34.3) 296 (66.7) 406 (98.8)
Median (interquartile range)
age, years
38 (33–43) 29 (25–34) 37 (32–42) 57 (52–63) 36 (31–41) 30 (24–36) 31 (27–36)
Injection drug use
Never 1537 (98.0) 150 (96.2) 780 (88.2) 425 (98.6) 22 (3.7) 444 (100) 403 (98.1)
Former 31 (2.0) 6 (3.9) 104 (11.8) 6 (1.4) 336 (57.1) 0 (0) 7 (1.7)
Current 0 (0) 0 (0) 0 (0) 0 (0) 231 (39.2) 0 (0) 1 (0.2)
Sexual orientation
Homosexual 1285 (82.0) 130 (83.3) 0 (0) 74 (17.2) 12 (2.0) 1 (0.2) 3 (0.7)
Bisexual 174 (11.1) 6 (3.9) 4 (0.5) 22 (5.1) 19 (3.2) 7 (1.6) 3 (0.7)
Heterosexual 107 (6.8) 16 (10.3) 875 (99.0) 328 (76.1) 558 (94.7) 433 (97.5) 405 (98.5)
Unknown 2 (0.1) 4 (2.6) 5 (0.6) 7 (1.6) 0 (0.0) 3 (0.7) 0 (0)
Sexual partners
Stable partner only 354 (22.6) 92 (59.0) 42 (4.8) 179 (41.5) 206 (35.0) 124 (27.9) 379 (92.2)
Stable and occasional 465 (29.7) 30 (19.2) 668 (75.6) 36 (8.4) 24 (4.1) 5 (1.1) 6 (1.5)
Occasional partner only 603 (38.5) 25 (16.0) 34 (3.9) 51 (11.8) 99 (16.8) 76 (17.1) 0 (0)
No partner 112 (7.1) 6 (3.9) 48 (5.4) 145 (33.6) 217 (36.8) 217 (48.9) 15 (3.7)
Unknown 34 (2.2) 3 (1.9) 92 (10.4) 20 (4.6) 43 (7.3) 22 (5.0) 11 (2.7)
Region of origin
Switzerland and
North-West Europe
1289 (82.2) 45 (28.9) 494 (55.9) 387 (89.8) 476 (80.8) 32 (7.2) 76 (18.5)
Southern Europe 130 (8.3) 8 (5.1) 95 (10.8) 35 (8.1) 69 (11.7) 0 (0) 4 (1.0)
Sub-Saharan Africa 8 (0.5) 4 (2.6) 144 (16.3) 2 (0.5) 4 (0.7) 399 (89.9) 199 (48.4)
Latin America 51 (3.3) 45 (28.9) 26 (2.9) 0 (0) 3 (0.5) 2 (0.5) 26 (6.3)
Asia, Eastern Europe 34 (2.2) 45 (28.9) 89 (10.1) 3 (0.7) 26 (4.4) 5 (1.1) 83 (20.2)
Other 56 (3.6) 9 (5.8) 36 (4.1) 4 (0.9) 11 (1.9) 4 (0.9) 22 (5.4)
Professiona
Self employed 249 (15.9) 16 (10.3) 115 (13.0) 109 (25.3) 25 (4.2) 47 (10.6) 38 (9.3)
Apprentice/trainee 5 (0.3) 15 (9.6) 5 (0.6) 0 (0) 32 (5.4) 15 (3.4) 9 (2.2)
Higher management 134 (8.6) 2 (1.3) 39 (4.4) 33 (7.7) 0 (0) 0 (0) 0 (0)
Middle management 333 (21.2) 2 (1.3) 65 (7.4) 63 (14.6) 25 (4.2) 16 (3.6) 14 (3.4)
Employee 835 (53.3) 64 (41.0) 647 (73.2) 202 (46.9) 440 (74.7) 238 (53.6) 142 (34.6)
Houseman/wife 0 (0) 7 (4.5) 0 (0) 10 (2.3) 16 (2.7) 39 (8.8) 165 (40.2)
Student 0 (0) 44 (28.2) 0 (0) 0 (0) 1 (0.2) 23 (5.2) 29 (7.1)
Other/unknown 12 (0.8) 6 (3.9) 13 (1.5) 14 (3.3) 50 (8.5) 66 (14.9) 14 (3.4)
Main source of income
Work 1416 (90.3) 47 (30.1) 756 (85.5) 173 (40.1) 72 (12.2) 58 (13.1) 3 (0.7)
Family support 1 (0.1) 93 (59.6) 30 (3.4) 0 (0) 15 (2.6) 2 (0.5) 361 (87.8)
Insurance/savings 145 (9.3) 13 (8.3) 91 (10.3) 256 (59.4) 494 (83.9) 377 (84.9) 41 (10.0)
Other/unknown 6 (0.4) 3 (1.9) 7 (0.8) 2 (0.5) 8 (1.4) 7 (1.6) 6 (1.5)
Number of participants (%) are shown unless otherwise indicated. Analysis based on all 4,483 participants enrolled in the Swiss HIV Cohort
Study since 1 January 2000
a Current or last held profession
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groups: older heterosexual men, single migrants from sub-
Saharan Africa, migrant women from several continents
who lived in stable partnerships and a group of hetero-
sexual men and women mainly from Switzerland. Finally,
in support of our third hypothesis, we found that group
membership was associated with relevant treatment out-
comes such as degree of immunodeficiency when starting
ART, virologic response to ART, loss to follow-up and
mortality. Of note, virologic suppression and adherence
was worse and loss to follow-up higher in single migrants
from sub-Saharan Africa than in the other groups pre-
dominantly infected through heterosexual contacts, and
more similar to patients infected through IDU.
Strengths and Weaknesses
A comparison of cohort data with official AIDS notifications
indicated that about 70% of all individuals living with AIDS
in Switzerland participate in the SHCS [25], and a recent
comparison with drug sales data showed that 75% of anti-
retroviral drug prescriptions in Switzerland can be attributed
to study participants [20]. The findings from our study
should therefore be applicable to the HIV-infected popula-
tion in the country, and possibly also to HIV-infected
patients starting ART in other industrialized settings.
Our study identified groups that are more informative
than the widely used categories of presumed transmission.
For example, there were no clear differences across
transmission groups in virologic response to ART. Such
differences, however, emerged across the groups identified
through latent class analysis. Also, the increased mortality
(adjusted for age) in heterosexually infected participants is
explained by the group of older heterosexual men, and not
a general phenomenon. Patients with a history of IDU
remain an important risk group, and the inclusion of IDUs
largely determined the prevalence of HCV infection in the
different groups. In contrast, the prevalence of HBV
infection was driven by the region of origin of patients.
LCA is related to other clustering techniques but has a
number of advantages. LCA is based on a statistical model
and uses objective criteria to identify the optimal number
of classes. Furthermore, the method can handle categorical
data, accommodates missing values and allows estimating
the probability that an individual belongs to a certain
group. The decision which variables to include in the
model is subjective, however. We selected variables and
their categories a priori to avoid bias, and made no changes
later on. Results are based on self-reported information on
adherence, sexual risk behavior and drug use provided
during an interview with a clinician, which is a limitation
of our study. Self-reports can be subject to recall bias or
social desirability bias. Such bias is, however, probably not
substantial: self-reported adherence correlates well with
suppression of viral load [26] and longitudinal analyses
showed that initiation of IDU was associated with wors-
ening adherence [27].
The information available in the SHCS was rich and
covered a wide range of socioeconomic and behavioral
Table 2 CD4 cell count, clinical stage and prevalence of hepatitis infection at start of ART in socio-behavioral and transmission groups
CD4 cell count (cells/ll) Clinical stage Hepatitis serology
N Median (IQR) \200 cells/ll CDC stage C Hepatitis C Hepatitis B
Socio-behavioral groups
Older homo- and bisexual men 630 220 (146–305) 246/581 (42.3) 95/630 (15.1) 25/617 (4.1) 30/595 (5.0)
Younger gay men 50 199 (109–264) 22/44 (50.0) 4/50 (8.0) 1/49 (2.0) 4/49 (8.2)
Heterosexual men and women 331 175 (74–282) 169/295 (57.3) 71/331 (21.5) 45/327 (13.8) 10/324 (3.1)
Older heterosexual men 176 219 (126–300) 71/160 (44.4) 42/176 (23.9) 12/176 (6.8) 7/171 (4.1)
Injection drug users 174 202 (108–277) 73/150 (48.7) 29/174 (16.7) 148/167 (88.6) 12/172 (7.0)
Single migrants 123 208 (116–291) 52/108 (48.2) 29/123 (23.6) 5/121 (4.1) 13/121 (10.7)
Migrant women in partnership 149 225 (146–330) 49/132 (37.1) 23/149 (15.4) 5/147 (3.4) 12/147(8.2)
P \0.001 0.001 0.008 \0.001 0.028
Transmission groups
Men who have sex with men 648 219 (147–297) 251/593 (42.3) 99/648 (15.3) 24/637 (3.8) 34/613 (5.6)
Heterosexual contact 748 200 (106–299) 327/670 (48.8) 142/748 (19.0) 56/738 (7.6) 39/733 (5.3)
Injection drug use 166 199 (108–277) 73/145 (50.3) 26/166 (15.7) 152/161 (94.4) 11/164 (6.7)
Other/unknown 71 202 (84–326) 31/62 (50.0) 26/71 (36.6) 9/68 (13.2) 4/69 (5.8)
P 0.07 0.08 \0.001 \0.001 0.92
Number of participants (%) are shown unless otherwise indicated. Analysis based on 1,633 participants who were treatment naı¨ve and started
ART at or after enrolment in the Swiss HIV Cohort Study. P values from Kruskal–Wallis tests for continuous variables and v2 tests for
categorical variables
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aspects. Groupings remained robust as the number of cat-
egories increased, and although groups are not mutually
exclusive, membership probabilities were generally high.
Since LCA treats all included variables equally, some
patients were allocated to groups that are counter-intuitive
(for example a few men were classified in the group of
migrant women). The mixed group was heterogeneous and
median membership probability was low for this group. It
is thus not certain that all groups are meaningful and
reproducible, and further research into these groups is
needed, for example in other populations of HIV-infected
patients and through qualitative research.
Methods and Results in Context with Other Literature
Clinical and epidemiological research is generally con-
cerned with identifying single variables that are associated
with the outcome of interest after adjusting for other
variables [28]. This approach has also been successful in
HIV medicine: the CD4 cell count, for example, is the
single strongest risk factor for disease progression, the
basis for determining when to start ART [29, 30], and for
assessing prognosis [31]. Our study addressed the question
whether socio-behavioral variables could help explain the
variation of CD4 cell counts at start of ART, and of pro-
gression to death. Rather than analyzing the independent
contribution of individual socio-behavioral variables, for
example the mode of HIV transmission, we identified
groups of patients that are similar with respect to many
socio-behavioral characteristics. Our approach is therefore
more closely related to clinical intuition and experiential
clinical reasoning than the usual analysis of individual risk
factors [32].
Previous analyses of the Swiss HIV cohort showed that
virologic response to ART was poorer in migrants from
sub-Saharan Africa [33] and in patients infected through
IDU [2]. Another study showed that rates of progression to
AIDS or death were lower in patients in stable partnerships
compared to other patients [34]. Our results confirm and
extend these results: the virologic response in migrants
living in stable relationships and levels of adherence were
comparable to other sexually infected groups, but poorer in
single migrants. Similarly, the socio-behavioral character-
istics and outcomes of some former IDUs were closer to
the group of heterosexual men and women, than to the
group of IDUs, in line with the observation that virologic
Box 1 Description of socio-behavioral groups
The groups are labelled according to their most pertinent characteristics. Medians (interquartile range) are given for age and the probability of
belonging to the group.
1) ‘‘Older gay and bisexual men’’ (n = 1,568 participants, 35.0%)
The median age at enrolment was 38 years (33–43 years). The members of this group are mainly from Switzerland and predominantly gay.
Many have occasional sexual partners only. They are employed or self-employed. The median probability of belonging to the group was
0.98 (0.91–0.99).
2) ‘‘Younger gay men’’ (n = 156 participants, 3.5%)
The median age was 29 years (25–34 years). The majority is from Latin America, Asia and Eastern Europe. They are employed or students,
and the majority have stable partners. Median probability of belonging to the group was 0.96 (0.73–1.00).
3) ‘‘Heterosexual men and women’’ (n = 884 participants, 19.7%)
The median age was 37 years (32–42 years). The majority is from Switzerland and North-West Europe. They are employed or self-
employed and the majority report a stable and occasional partner. The group includes some individuals with a history of past injection drug
use. Median probability of belonging to the group: 0.82 (0.63–0.92).
4) ‘‘Older heterosexual men’’ (n = 431, 9.6%)
The median age was 57 years (52–63 years). The majority (74%) are heterosexual men from North-West Europe, but the group also
includes some gay men (20%). Most of them are employees or self-employed, some live from pensions or savings, and many are in stable
partnerships. Median probability of belonging to the group: 0.88 (0.68–0.96).
5) ‘‘Injection drug users’’ (n = 589 participants, 13.1%)
The median age was 36 years (31–41) years. Most are former users, about a third report current injection drug use. They are mainly from
Switzerland. Many receive support from social insurances. The majority have either stable partners or no partner. Median probability of
belonging to the group: 0.99 (0.95–1.00).
6) ‘‘Single migrants’’ (n = 444 participants, 9.9%)
The median age was 30 years (24–36 years). The majority are heterosexual women and men from sub-Saharan Africa. They are employed
or live from social insurance, unemployment benefits, or savings. Two thirds report no partner or occasional partners only. Median
probability of belonging to the group: 0.92 (IQR 0.70-0.98).
7) ‘‘Migrant women in partnerships’’ (n = 411, 9.2%)
The median age was 31 years (27–36 years). Many are married, some are employed. The majority are from sub-Saharan Africa, Asia and
Eastern Europe. Over 90% live in a stable partnership. Median probability of belonging to the group: 0.97 (IQR 0.91–1.00).
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response to ART is better in former IDUs and IDUs
attending opiate substitution programmes than in individ-
uals who continue to inject drugs [21]. The group domi-
nated by older heterosexual men also included some gay
and bisexual men who were otherwise more similar to this
group than to the group of older gay and bisexual men. The
prevalence of HCV infection was higher in the group of
older heterosexual men and this group might therefore
include some men with a non-disclosed history of IDU.
Mortality in this group was increased compared to older
gay and bisexual men, even after adjusting for age.
Late diagnosis of HIV and initiation of ART with
advanced immunodeficiency is well documented in low-
income settings [35], but also an issue in industrialized
countries [36, 37]. For example, a French study found that
36% of participants were enrolled with a CD4 cell count
below 200 cells/ll, or an AIDS defining event [36]. A pre-
vious analysis of the SHCS showed that among treatment-
naı¨ve participants with CD4 cell counts above 200 cells/ll,
20% dropped below this threshold before starting ART [38].
Heterosexual transmission was not associated with late ini-
tiation of ART in the previous study. Our analysis indicates
that this is an important issue in one group of heterosexually
infected patients, but less so in other groups. This could be
due to the fact that members of this group and their health
care providers do not generally consider them to be ‘at risk’
and thus not test for HIV as frequently as in other groups.
Implications for ART and Future Research
Our study has several implications for the provision of
ART to different groups of HIV-1 infected patients. Viro-
logic response to ART was worse in migrants with occa-
sional partners or no partners; presumably because of lower
levels of adherence to ART. Interventions to increase
migrants’ ability to adhere to ART should therefore be
considered. Although health care insurance is mandatory
for all people living in Switzerland and subsidized by the
government, some immigrants have a fragile legal status
and language barriers and social norms may be a barrier for
optimal adherence and care. Other European studies have
shown worse treatment outcomes for ethnic minorities and
immigrants [39, 40]. Targeted interventions could include
culturally adapted adherence counseling, self-help or
community groups, general improvement of access to
health information and involvement of family members
and people who will be trusted by the patient [41].
The reasons for the high rate of loss to follow-up and
whether or not ART is continued in patients leaving the
cohort should be examined. Interventions to minimize loss
to follow-up could include scheduling more frequent fol-
low-up visits in vulnerable groups. Preventing loss to fol-
low-up in immigrants may be more difficult: a previous
SHCS study has shown that many immigrants were asylum
seekers and the main reason for leaving the country was the
rejection of applications for asylum [42]. The increased
mortality in older heterosexual men, which remained after
adjusting for age, CD4 cell count and other risk factors, is
an intriguing finding: further research into the excess
mortality observed in this group is required. Finally, our
study highlights the continued need for efforts to improve
outcomes in patients infected through IDU, particularly
patients who continue to inject drugs.
In conclusion, socio-behavioral groups of HIV-1 infected
patients can be identified that differ with respect to the
response to ART, adherence, loss to follow-up and mortality.
These groups allow insights above what can be gleaned from
analyses of the traditional transmission groups and identify
patients who may benefit from targeted interventions.
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